Skip to content
Screener

Monte Rosa Therapeutics, Inc. GLUE Other operating expenses

Other operating expenses at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$103.25M+11.8%
Arvinas logo
ArvinasARVN
$79.4M-32.4%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$140.61M+46.4%
Vor Biopharma logo
Vor BiopharmaVOR
$35.16M+5.6%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$15.55M+8.0%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$159.55M+40.2%

Other financials

Income statement

See full
Revenue$9.0M-61.3%
Operating income-$49.1M-216%
Net income-$43.4M-253%
EPS (diluted)-$0.43-187%

Balance sheet

See full
Cash & equivalents$90.1M+29.8%
Total debt$38.0M-7.6%
Total equity$487.3M+81.8%
Total assets$691.2M+92.2%

Cash flow

See full
Operating cash flow-$44.1M-27.1%
CapEx$4.7M+179%
Free cash flow-$48.8M-34.1%

Valuation

See full
Market cap$1.33B+395%
Enterprise value$1.28B+432%
P/S46.2×+44.7×

Profitability

See full
Operating margin-633%
Net margin-560.8%
FCF margin-111.7%-125pp

Returns & leverage

See full
Return on equity-42.7%
Debt / equity0.1×-0.1×
Current ratio10.6×+3.4×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:09 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336711
(in thousands, except share and per share amounts)Three months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Operating expenses:
Research and development47,96430,65392,03362,843
General and administrative10,1348,09520,30916,798
Total operating expenses58,09838,748112,34279,641
(Loss) income from operations(49,130)(15,554)(99,164)28,482
Other income:
Interest income5,9163,06811,5076,507
Foreign currency exchange gain251,390171,563

Item 1. Financial Statements

FAQ

What is Monte Rosa Therapeutics, Inc.'s other operating expenses?
Monte Rosa Therapeutics, Inc. (GLUE) reported other operating expenses of $58.1M in Q2 2026.
How has Monte Rosa Therapeutics, Inc.'s other operating expenses changed year-over-year?
Monte Rosa Therapeutics, Inc.'s other operating expenses increased by 49.9% year-over-year, from $38.75M to $58.1M.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s other operating expenses?
Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s other operating expenses has grown at a 25.0% compound annual growth rate (CAGR), from $72.88M to $177.88M.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.

Ask your AI about Monte Rosa Therapeutics, Inc.'s other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude